Nanotechnology Now - Press Release: "Increase patent revenue for oral and non oral drug delivery products"

Home > Press > Increase patent revenue for oral and non oral drug delivery products

Abstract:
Examining the latest developments in nanomedicine and enhancing in vivo circulation time, extending dissolution kinetics, and improving delivery with drug-porous nanocarriers, lipid-based compounds and biologics.

Increase patent revenue for oral and non oral drug delivery products

UK | Posted on March 4th, 2012

With less than a month to go join SMi at their 9th annual Controlled Release conference that will once again lead the way in examining the latest developments in nanomedicine and featuring fresh presentations from companies including GlaxoSmithKline, Lundbeck, Merck Serono and Genzyme.

Controlled Release will allow delegates to meet and network with key decision makers from the top pharmaceutical companies, as well as discuss & debate current issues such as challenges in drug formulation for oral delivery - where are we and what are the prospects for the future, challenges and opportunities for delivering biologics to the CNS and solutions for dissolution testing of non-oral formulations.

Network with key presenters within the pharmaceutical industry that includes:

• Peter Timmins, Executive Director, Drug Products, Science and Technology, Bristol-Myers Squibb
• Mark Wilson, Director, Collaboration Management, GlaxoSmithkline
• Simon Holland, Director, Process Understanding & Control, GlaxoSmithKline
• Bernd Riebesehl, Principal Fellow, Parenteral Dosage Forms, Pharmaceutical and Analytical Development, Novartis
• Mostafa Nakach, Head of the Pharmaceutical Engineering Group, Sanofi-Aventis
• Michael Keller, Senior Fellow, siRNA Project Leader, Technical Research and Development (TRD), Novartis
• Jonathan Brown, Senior Research Investigator, Bristol-Myers Squibb
• Tomas Landh, Director, Novo Nordisk
• Jan L. Powell, Director, Physiology, Shire HGT
• Lars Bauer, Senior Medical Director, Therapeutic Area CNS, UCB
• Karin Liltorp, Director, Preformulation, Lundbeck

####

For more information, please click here

Contacts:
Fateja Begum
Tel: +44 (0) 207 827 6184

Kellee Halliburton

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: